Real-world data reinforce SGLT2 inhibitors as first-line therapy for frail, older adults with heart failure with preserved ...

For patients with diabetes and early-stage pulmonary malignancies, administration of a sodium-glucose cotransporter 2 ...

In a study from Korea, adults with type 2 diabetes had a lower risk for autoimmune rheumatic diseases after starting an SGLT2 ...

SGLT2 inhibitors show significant benefits in older adults with cardiovascular disease, with consistent benefits across subgroups based on diabetes status or age, a meta-analysis shows.

SGLT2 inhibitors may worsen heart failure outcomes from chemotherapy, highlighting the need for further long-term studies on ...

Fibrosis occurs when inflammation activates immune cells and fibroblasts to release collagen and cytokines that remodel and ...

The diabetes drug empagliflozin (Jardiance) and an insulin nasal spray both showed promising effects on memory, brain health ...

Orforglipron, a novel oral GLP-1, was superior to dapagliflozin for reducing HbA1c in adults with type 2 diabetes ...

Novo Nordisk announced its oral GLP-1 has been approved by the FDA to reduce risk for major adverse cardiovascular events in ...

Novartis reports that Fabhalta® achieved the Phase III APPLAUSE-IgAN primary endpoint, showing slowed kidney-function decline ...

Researchers have identified that glucagon-like peptide-1 receptor agonists (GLP-1 RAs), which are widely used to control type ...

Eli Lilly has built the case for its oral GLP-1 agonist orforglipron with two more phase 3 readouts, including new data ...